Back to Annual Meeting

Back to Annual Meeting

APHA Scientific Session and Event Listing

Recorded presentation

Rosa Rodriguez-Monguio, PhD, School of Public Health, Ohio State University, 1841 Millikin Road, 459 Cunz Hall, Columbus, OH 43210, 614 247 4245, rmonguio@sph.osu.edu and Enrique C. Seoane Vazquez, PhD, College of Pharmacy and School of Public Health, Ohio State University, 500 West 12th Avenue, Columbus, OH 43210.

Purpose: This study analyzes the effect of the 2003 negotiation of antiretroviral drug (ARV) prices of the Andean Countries. The study objectives were: to assess the problems faced during the negotiation process, to evaluate the impact of the negotiation on prices paid by public programs, and to identify factors that made it difficult for countries to purchase ARVs at the negotiated prices and standards.

Data: The information derived from a bibliographic review and a survey of prices directed to the ministries of health.

Methods: Prices paid by public programs were analyzed by program, country and company. ARV purchases were converted to common units. Domestic currencies were converted to U.S. dollars.

Results: The negotiation achieved lower prices and higher quality and bioequivalence standards. In general, the public programs of the six countries analyzed did not purchase ARVs from the companies that participated in the negotiation, nor did they base purchases on the prices or quality and bioequivalence criteria established in the negotiation. Prices paid by the Andean countries' public programs in 2004 ranged from 84.7% to 4477.8% of the average negotiated prices, with a weighted average of 165.4%.

Policy Implications: Successful development and implementation of multinational price negotiations require that participant countries coordinate regulations and policies related to drug registration, quality and bioequivalence, international trade, intellectual property, and procurement. At the national level, more efficient use of resources could be achieved upon coordination of each country's various health care programs; improvement of the countries' epidemiological and information systems; and strengthening of the procurement and distribution systems.

Learning Objectives:

Learning Objectives
• To identify the problems faced during a multinational drug price negotiation
• To understand the national and international factors that make difficult the implementation of the results of a multinational negotiation
• To assess the value of drug prices negotiations as a way to reduce drug prices and increase access

Keywords: Access, HIV/AIDS

Presenting author's disclosure statement:

Any relevant financial relationships? No

Recorded presentation